Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of dapagliflozin + metformin versus XIGDUO XR in healthy Thai adults under fasting conditions
TCTR20260909005Phase 1Not yet recruiting
- Sponsor
- Dr. Sasitorn Kittivoravitkul
- Start
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dr. Sasitorn Kittivoravitkul. Primary endpoints: Maximum plasma concentration (Cmax) of dapagliflozin and metformin, Area under the plasma concentration-time curve from dosing to last observed concentration (AUC0-t) of dapagliflozin and metformin and 1 more. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
dapagliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20260909005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260909005.